These studies suggested that mutant PTEN causes an inadequate response to current anti-mutant BRAF kinase treatments in melanoma, supporting the notion that PTEN inactivation identifies a distinct clinically significant subset of melanomas, while implying that PTEN status may affect the molecular mechanism of late acquired resistance to BRAF inhibitor (BRAFi). Here, PTEN is linked to melanoma.